ASND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ascendis Pharma A/S (ASND) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong growth outlook, positive analyst sentiment, and robust revenue performance outweigh the short-term technical and options-based concerns.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 68.617, and moving averages are converging, suggesting no strong directional bias. The stock is trading near its resistance level (R1: 229.029), with support at 221.397. Short-term trends indicate a potential minor pullback (-1.97% in the next day, -2.15% in the next week) but a positive outlook for the next month (+5.15%).
Analysts have raised price targets significantly, with multiple firms maintaining 'Buy' or 'Outperform' ratings.
Strong growth in Yorvipath adoption and management's guidance for EUR 500M operating cash flow in
Anticipated FDA approval for TransCon CNP by February 28, 2026, and a timely launch afterward.
Revenue for 2025 reached €720 million, driven by Yorvipath demand.
Hedge funds are heavily selling, with a 565.41% increase in selling activity last quarter.
Insiders remain neutral, with no significant trading trends.
Competitor BridgeBio Pharma reported positive Phase 3 trial results for a competing achondroplasia treatment, which could affect market share.
In Q4 2025, revenue remained flat YoY at €247.5M, with a gross margin of 90.47%. Net income improved but remained negative at -€33.56M, and EPS was -0.55. While profitability is still a concern, the company is showing strong revenue growth potential.
Analysts are highly optimistic, with multiple firms raising price targets (e.g., Stifel to $325, Wells Fargo to $330). The average price target is significantly above the current price of $229.97, reflecting strong confidence in future growth driven by Yorvipath and TransCon CNP.
